Pharmaceutical
Financial Results (Q1 YTD/FY2026)
Financial Results (Q1 YTD/FY2026)
About this update from Astellas Pharma Inc.
Astellas Pharma Inc. (4503) Press Release View Attachment
View stock analysis, news, and events for Astellas Pharma Inc.
More from Astellas Pharma Inc.
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastati...
August 24, 2026
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin...
July 10, 2026